Search Results for "action"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for action. Results 561 to 570 of 1197 total matches.

Infliximab (Remicade) for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 1999  (Issue 1047)
, November 20, 1998). MECHANISM OF ACTION — Tumor necrosis factor alpha (TNFα), a pro-inflammatory protein ...
Infliximab, a monoclonal antibody that inhibits tumor necrosis factor, has received an accelerated approval from the FDA for intravenous treatment of moderate to severe Crohn's disease refractory to other medical treatment.
Med Lett Drugs Ther. 1999 Feb 26;41(1047):19-20 |  Show IntroductionHide Introduction

Orlistat for Obesity

   
The Medical Letter on Drugs and Therapeutics • Jun 18, 1999  (Issue 1055)
OF ACTION — A pentanoic acid ester, orlistat binds to gastric and pancreatic lipases, inhibiting ...
Orlistat, a lipase inhibitor that decreases absorption of fat from the gastrointestinal tract, is now available for treatment of obesity.
Med Lett Drugs Ther. 1999 Jun 18;41(1055):55-6 |  Show IntroductionHide Introduction

Laser Hair Removal

   
The Medical Letter on Drugs and Therapeutics • Jul 30, 1999  (Issue 1058)
Aesth Dermatol Cosmet Surg, 1:3, 1999). MECHANISM OF ACTION — Several laser systems are used for hair ...
A long-pulse ruby laser (EpiLaser), has been cleared by the FDA for use in "permanent hair reduction."
Med Lett Drugs Ther. 1999 Jul 30;41(1058):67-70 |  Show IntroductionHide Introduction

Spironolactone for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Sep 10, 1999  (Issue 1061)
than 2.5 mg/dl. The most common adverse effects related to the anti-androgenic action ...
Spironolactone, an aldosterone receptor antagonist, has been FDA-approved for many years for treatment of edema, hypertension and primary hyperaldosteronism. Recently, it was reported to improve morbidity and mortality in patients with severe heart failure.
Med Lett Drugs Ther. 1999 Sep 10;41(1061):81-2 |  Show IntroductionHide Introduction

Phytoestrogens

   
The Medical Letter on Drugs and Therapeutics • Feb 21, 2000  (Issue 1072)
OF ACTION — Phytoestrogens generally act as weak estrogens, but may also have antiestrogenic effects (J ...
Phytoestrogens, plant compounds that are converted to estrogens in the gut, are widely promoted as "natural"substitutes for estrogen in hormone replacement therapy.
Med Lett Drugs Ther. 2000 Feb 21;42(1072):17-8 |  Show IntroductionHide Introduction

Exemestane For Advanced Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2000  (Issue 1076)
:61, 1996) and letrozole (Femara − Medical Letter, 40:43, 1998). MECHANISM OF ACTION — Aromatase ...
The FDA has approved exemestane, an aromatase inhibitor, for the treatment of postmenopausal women with advanced breast cancer that has progressed during treatment with tamoxifen.
Med Lett Drugs Ther. 2000 Apr 17;42(1076):35-6 |  Show IntroductionHide Introduction

Ciclopirox (Penlac) Nail Lacquer for Onychomycosis

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2000  (Issue 1080)
, 1998). Its exact mechanism of action is unknown. Less than 5% of a topical dose is absorbed ...
Ciclopirox nail lacquer (Penlac - Dermik) has been approved by the FDA for treatment of mild-to-moderate onychomycosis due to Trichophyton rubrum, without involvement of the lunula. The drug has been available for many years as a lotion and cream (Loprox) for treatment of cutaneous fungal infection
Med Lett Drugs Ther. 2000 Jun 12;42(1080):51-2 |  Show IntroductionHide Introduction

Rivastigmine (Exelon) For Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000  (Issue 1089)
Letter 1997; 39:53). MECHANISM OF ACTION — Cognitive deficits in Alzheimer’s disease ...
Rivastigmine tartrate (Exelon - Novartis), a carbamate-based cholinesterase inhibitor, is now being marketed for treatment of patients with dementia due to Alzheimer's disease.
Med Lett Drugs Ther. 2000 Oct 2;42(1089):93-4 |  Show IntroductionHide Introduction

Galantamine (Reminyl) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jun 25, 2001  (Issue 1107)
2001. MECHANISM OF ACTION — Alzheimer’s disease is associated with diminished brain acetylcholine ...
Galantamine hydrobromide (Reminyl), a tertiary alkaloid and phenanthrene derivative extracted from daffodil bulbs, is now being marketed for oral treatment of mild to moderate Alzheimer's disease. Galantamine is the fourth acetylcholinesterase inhibitor approved for this indication.
Med Lett Drugs Ther. 2001 Jun 25;43(1107):53-4 |  Show IntroductionHide Introduction

Update on Glucosamine For Osteoarthritis

   
The Medical Letter on Drugs and Therapeutics • Dec 10, 2001  (Issue 1120)
, treat or prevent any disease. MECHANISM OF ACTION — In vitro, glucosamine stimulates cartilage cells ...
Since the last Medical Letter article on glucosamine for osteoarthritis (vol.39, page 91, September 26, 1997), more data have become available. Glucosamine is available in US pharmacies and health food stores as sulfate, hydrochloride or n-acetyl salt.
Med Lett Drugs Ther. 2001 Dec 10;43(1120):111-2 |  Show IntroductionHide Introduction